** Shares of Chinese pharmaceutical products developer Ascletis Pharma Inc 1672.HK jump 8.7% to HK$7.99, their highest since March 2019
** Stock on course for the biggest one-day gain since March 3; on track for third straight session of rise
** Ascletis announces positive topline results of Phase 1B studies of weight loss drug candidate ASC47 monotherapy in Australia
** Says U.S. Food and Drug Administration has cleared the U.S. Investigational New Drug application for ASC47 in combination with semaglutide for the treatment of obesity
** Hong Kong's healthcare index .HSCIH and Hang Seng Index .HSI both slip 0.1%
** Stock up 144.2% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。